Form 8-K Esperion Therapeutics, For: Aug 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Needham & Company Upgrades Esperion Therapeutics (ESPR) to Strong Buy; Shares Will Rebound
August 10, 2015 7:08 AM EDTNeedham & Company upgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Strong Buy with a price target of $130.00.
Analyst Chan Messer commented, "ESPR shares have recently pulled back over regulatory concerns. Some investors feel that an evolution of thinking at the FDA about... More
Chardan Capital Trims PT on Esperion (ESPR) Following Q2 Results, TAK-475 Failure Concerning for ETC-1002
August 7, 2015 8:30 AM EDTChardan Capital affirms its Sell rating on Esperion (Nasdaq: ESPR) and cuts its price target from $45 to $40 following Q2 results.
Analyst Gbola Amusa commented, Esperion reported 2Q basic and diluted EPS of -$0.55, versus our expectation of -$0.56. A share count of... More
